BrightFocus Foundation Statement on Biogen Alzheimer’s Announcement
“BrightFocus is highly encouraged by Biogen’s announcement today that clinical trials of its experimental drug aducanumab reduced cognitive decline in some Alzheimer’s patients through improved cognition, memory, and activities of daily living.
This news is a powerful reminder that research equals hope, no matter how daunting the medical and scientific challenge. The teaming up of innovative researchers and dedicated clinical trial volunteers can lead to life-changing breakthroughs.
BrightFocus, through its Alzheimer’s Disease Research program, helped lay the groundwork for possible treatments like this, and while there is still a long way to go in ending this disease, this is a truly promising development.”